TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX) will present in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:00 p.m. ET. A live webcast will stream at the company’s Events and Presentations page and an archived replay will be available for 90 days.

News Market Reaction – TCRX

-0.93%

1 alert

-0.93% Session close to close

-2.6% Trough Tracked

$60.88M Market Cap

0.0x Rel. Volume

In the Apr 8 session, TCRX declined 0.93%, reflecting a mild negative market reaction. Argus tracked a trough of -2.6% from its starting point during tracking.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights TScan’s participation in the 25th Annual Needham Virtual Healthcare Con...

Analysis

This announcement highlights TScan’s participation in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, adding another investor-relations touchpoint via a webcast with a 90-day replay. In recent months, the company has paired such appearances with clinical and financial updates on its ALLOHA™ heme program and TSC-101 pathway. Investors may watch upcoming data disclosures, pivotal trial initiation timing, and capital planning steps as key markers for the story.

Key Figures

Conference date: April 15, 2026 Conference time: 3:00 p.m. Eastern Time Replay availability: 90 days +1 more

4 metrics

Conference date April 15, 2026 Needham Virtual Healthcare Conference fireside chat

Conference time 3:00 p.m. Eastern Time Scheduled start time of fireside chat

Replay availability 90 days Archived webcast replay on company website

Conference edition 25th Annual Needham Virtual Healthcare Conference iteration

Historical Context

5 past events · Latest: Mar 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 04	Earnings and update	Positive	+4.3%	Q4/FY25 results, IND clearances, and cash runway into H2 2027.
Feb 26	Clinical and FDA	Positive	+0.0%	Cohort C completion in ALLOHA™ and FDA IND clearance for TSC-102.
Feb 25	Conference participation	Neutral	+5.7%	TD Cowen conference fireside chat with webcast and 90-day replay.
Dec 06	Clinical data update	Positive	-7.4%	Positive ALLOHA™ Phase 1 TSC-101 data and FDA-agreed pivotal design.
Dec 03	KOL event	Positive	+6.9%	Virtual KOL event on ALLOHA™ data, manufacturing, and pivotal trial plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent TCRX news has often seen positive price alignment, though there are notable divergences on some clinically positive updates.

Recent Company History

Over the last six months, TScan has reported multiple clinical and corporate milestones. Earnings on Mar 4, 2026 highlighted revenue growth and an extended cash runway, with a 4.35% positive reaction. Clinical updates on ALLOHA™ and IND clearances in late February drew a flat reaction, while a conference appearance on Feb 25, 2026 saw shares rise 5.71%. Earlier ALLOHA™ Phase 1 data in December showed mixed price responses despite generally positive clinical trends. Today’s Needham conference notice fits the pattern of ongoing investor outreach and visibility efforts.

Key Terms

t cell receptor, tcr-t

2 terms

t cell receptor medical

"focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies"

A T cell receptor is a protein sensor on the surface of certain immune cells that recognizes small pieces of foreign or abnormal material, like fragments of a virus or a cancer cell, and helps trigger an immune response. Investors care because therapies and diagnostics that target or use these receptors act like reprogramming a security scanner to find specific threats, so success or failure in developing safe, effective T cell receptor–based drugs or tests can strongly affect a biotech company's value.

tcr-t medical

"development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer"

TCR‑T is a type of engineered cell therapy where a patient’s T cells are reprogrammed to carry specific T‑cell receptors that recognize fragments of disease proteins presented on the surface of cells. Think of it as giving immune cells a custom key to find and attack cells displaying a particular molecular “badge.” For investors, TCR‑T represents a high‑precision, potentially powerful treatment approach with significant commercial upside but also complex manufacturing, regulatory hurdles and safety risks that can affect development timelines and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 25^th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 3:00 p.m. Eastern Time.

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company is in early stages of developing methods for in vivo engineering to treat solid tumors. The Company is also applying its target discovery platform to discover novel targets in various T cell-mediated autoimmune disorders.

Investor and Media Contact

Caileigh Dougherty
857-399-9890
ir@tscan.com

FAQ

When will TScan Therapeutics (TCRX) present at the Needham Virtual Healthcare Conference?

TScan will present on April 15, 2026 at 3:00 p.m. Eastern Time. According to the company, the presentation is a fireside chat format and is scheduled as part of the conference’s virtual program for investor engagement.

How can investors watch the TScan (TCRX) fireside chat on April 15, 2026?

Investors can watch via a live webcast on the company’s Events and Presentations webpage. According to the company, the webcast will be available at ir.tscan.com with an archived replay posted for 90 days after the event.

Will TScan (TCRX) provide a replay of the Needham conference presentation?

Yes, an archived replay will be available for 90 days following the event. According to the company, the replay will be posted on the company website’s Events and Presentations section for on-demand viewing.

What topic will TScan Therapeutics (TCRX) cover at the Needham Virtual Healthcare Conference?

The company will participate in a fireside chat discussing recent developments and strategy. According to the company, the session will cover clinical-stage TCR-T programs and the company’s clinical and corporate updates for investors.

Where is the webcast for TScan (TCRX) hosted for the April 15, 2026 event?

The webcast is hosted on the company’s investor Events and Presentations webpage at ir.tscan.com. According to the company, the page will provide live access and the subsequent 90-day archived replay for investors.